Canton Strategic (CNTN) vs Foghorn Therapeutics (FHTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Canton Strategic (CNTN) has outperformed Foghorn Therapeutics (FHTX) over the past year, losing 50.6% versus a loss of 62.8%. Foghorn Therapeutics is the larger company by market cap ($103.1 million vs $98.8 million), about 1.0 times the size. On valuation, Foghorn Therapeutics trades at a lower trailing P/E (19.1x vs 20.2x for Canton Strategic).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTN | FHTX |
|---|---|---|
| Share price | $1.21 | $1.72 |
| Market cap | $98.78M | $103.14M |
| 1-day change | -1.63% | -3.37% |
| YTD return | -60.07% | -68.15% |
| 1-year return | -50.61% | -62.77% |
| 5-year return | — | -87.36% |
| P/E ratio (TTM) | 20.17 | 19.11 |
| EPS (TTM) | $0.06 | $0.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $30.91M |
| Revenue growth (YoY) | — | +36.75% |
| Net income (latest FY) | $-35.92M | $-74.28M |
| Operating margin | — | -279.49% |
| Net margin | — | -240.33% |
| 52-week high | $5.83 | $7.61 |
| 52-week low | $1.19 | $1.66 |
| Distance from 52-week high | -79.25% | -77.40% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +142.44% |
| Average volume | 763.63K | 843.73K |
| Shares outstanding | 81.64M | 59.96M |
| Employees | 12 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CNTN has outperformed FHTX by 12.2 percentage points over the past year.
About Canton Strategic
CNTN stock →Canton Strategic Holdings, Inc. focuses on advancing institutional blockchain adoption and digitizing financial markets in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
CNTN vs FHTX FAQ
Which is bigger, Canton Strategic or Foghorn Therapeutics?
Foghorn Therapeutics (FHTX) is larger, with a market capitalization of $103.14M compared with $98.78M for Canton Strategic (CNTN).
Which stock has performed better over the past year, CNTN or FHTX?
CNTN returned -50.61% over the past 12 months, compared with -62.77% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CNTN or FHTX?
FHTX has the lower trailing P/E at 19.1, versus 20.2 for CNTN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Canton Strategic and Foghorn Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.